ArticleJournal of hepatocellular carcinoma2026
Development and Validation of a HAUS-Related Prognostic Signature in Liver Hepatocellular Carcinoma: A Multi-Omics Integration from Pan-Cancer Analysis to Single-Cell Resolution.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The HAUS family proteins (HAUS1-HAUS8) are essential for mitotic spindle microtubule nucleation. Although HAUS dysregulation has been linked to tumor progression, whether these oncogenic functions are conserved or tissue-specific remains unclear. Therefore, a pan-cancer analysis is needed to identify universal HAUS drivers and context-dependent members for precision oncology. Methods: We systematically evaluated the expression and prognostic significance of all eight HAUS genes across 33 cancer types using TCGA data. Focusing on liver hepatocellular carcinoma (LIHC), we identified molecular subtypes based on HAUS co-expression patterns and characterized their associations with clinicopathological features, the tumor microenvironment (TME), immune checkpoint expression, and therapeutic response. A HAUS-related prognostic signature was developed using LASSO and Cox regression analyses and validated in independent ICGC cohorts. Regulatory relationships among HAUS members and key signature genes were experimentally validated using immunohistochemistry and Western blotting. Results: Most HAUS members were overexpressed across multiple cancers and correlated with poor clinical outcomes. In LIHC, two HAUS-based subtypes differed significantly in survival, clinicopathological profiles, immune features, mutational burden, stemness indices, and predicted therapeutic response. A prognostic signature comprising DTYMK and SPP1 effectively stratified LIHC patients into distinct risk groups, with the high-risk group showing significantly worse survival. A nomogram integrating the HAUS-related risk score with clinicopathological variables demonstrated strong predictive performance. Recombinant osteopontin induced HAUS1 and DTYMK expression in LIHC cell lines, supporting a functional SPP1-HAUS1/DTYMK axis. Conclusion: This study establishes the broad oncogenic relevance of HAUS genes across cancers and demonstrates that a HAUS-based signature enables prognostic stratification in LIHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.